Acute myeloid leukemia
Conditions
Interventions
Sponsors
Tianjin First Central Hospital
Eligibility
Sex/Gender
All
Age
2 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Compliance with patients with refractory and relapsed acute myeloid leukemia; the definition of refractory is: (1) Treat patients who have not achieved partial remission after 2 courses of treatment with a standard remission induction program. (2) Relapse within 6 months after the first remission is also called early relapse. (3) Those who relapsed 6 months after the first remission, but failed to treat again with the original remission induction program. (4) Relapsed multiple times. Recurrence is defined as: patients who have achieved complete remission after treatment, with more than 5% of leukemia cells in the bone marrow, also known as intramedullary recurrence; or the appearance of leukemia lesions outside the bone marrow, also known as extramedullary recurrence (usually in the central nervous system, Testicular leukemia is the most common); 2. The diseased cells were confirmed to express CLL1/CD33/CD123/NKG2D/LILRB2(CD85d)/LILRB4 (CD85k)/ADGRE2/CCR1 targets; 3. KPS > 60 points; 4. The expected survival time is more than 3 months; 5. Gender is not limited, age 2-75 years old; 6. Patients who are clinically diagnosed as high-risk type, relapse and refractory type, or who do not have the conditions to receive standard treatment; 7. No serious mental disorders; 8. Sufficient heart, liver and kidney function (a. Liver function: ALT/AST = 95%; d. Heart function: left ventricular ejection fraction (LVEF) >= 40%;); 9. There are no other serious diseases that conflict with this plan (such as autoimmune diseases, immunodeficiency, organ transplantation); 10. Able to cooperate with trial management and follow-up; 11. The patient voluntarily participated in the study and signed an informed consent form.
Exclusion criteria
Exclusion criteria: (1) History of other malignant tumors; (2) Uncontrolled active infection; (3) Those with underlying diseases that require systemic application of glucocorticoids; (4) Acute and chronic GVHD; (5) T cell inhibitor therapy; (6) Women during pregnancy and lactation; (7) Patients with hepatitis B during the active period; (8) Other conditions deemed unsuitable to participate in the study by other researchers (HIV infection, intravenous drug addicts, etc.), or other conditions that affect the analysis of the results of this clinical study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall remission rate;Progression Free Survival; | — |
Countries
CHINA
Contacts
Public ContactZhao Mingfeng
Tianjin First Central Hospital
Outcome results
None listed